Azithromycin Resistance and Decreased Ceftriaxone Susceptibility in *Neisseria gonorrhoeae*, Hawaii

Technical Appendix

**Technical Appendix Table.** Phenotypic antimicrobial susceptibility and genetic strain typing of *Neisseria gonorrhoeae* isolates with high-level resistance to azithromycin and decreased in vitro susceptibility to ceftriaxone, Hawaii

<table>
<thead>
<tr>
<th>Strain/SRA Accession Number</th>
<th>MIC (MIC, µg/mL) (susceptibility classification)†</th>
<th>Test type</th>
<th>Azithromycin</th>
<th>Cefixime</th>
<th>Ceftriaxone</th>
<th>Ciprofloxacin</th>
<th>Gentamicin</th>
<th>Penicillin</th>
<th>Tetracycline</th>
<th>NG-MAST</th>
<th>MLST</th>
</tr>
</thead>
<tbody>
<tr>
<td>GCWGS_0156/SRR4048856</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R) 0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>16 (R) 8</td>
<td>&gt;64 (R) 2 (R)</td>
<td>SC14121</td>
<td>ST1901</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest‡</td>
<td>&gt;256 (R) 0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCWGS_0161/SRR4048862</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R) 0.06 (S) 0.06 (S)</td>
<td>8 (R) 4</td>
<td>&gt;64 (R) 2 (R)</td>
<td>SC14121</td>
<td>ST1901</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest‡</td>
<td>&gt;256 (R) 0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCWGS_0163/SRR4048864</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R) 0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>16 (R) 8</td>
<td>&gt;64 (R) 2 (R)</td>
<td>SC14121</td>
<td>ST1901</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest‡</td>
<td>&gt;256 (R) 0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCWGS_0169/SRR4048869</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R) 0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>16 (R) 8</td>
<td>&gt;64 (R) 2 (R)</td>
<td>SC14121</td>
<td>ST1901</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest‡</td>
<td>&gt;256 (R) 0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCWGS_0180/SRR4048880</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R) 0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>16 (R) 8</td>
<td>&gt;64 (R) 2 (R)</td>
<td>SC14121</td>
<td>ST1901</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest‡</td>
<td>&gt;256 (R) 0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCWGS_0181/SRR4048881</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R) 0.06 (S) 0.06 (S)</td>
<td>8 (R) 4</td>
<td>&gt;64 (R) 2 (R)</td>
<td>SC14121</td>
<td>ST1901</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest‡</td>
<td>&gt;256 (R) 0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCWGS_0182/SRR4048882</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R) 0.06 (S) 0.03 (S)</td>
<td>16 (R) 4</td>
<td>&gt;64 (R) 2 (R)</td>
<td>SC14121</td>
<td>ST1901</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest‡</td>
<td>&gt;256 (R) 0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCWGS_0322/SRR5259797</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R) 0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>16 (R) 8</td>
<td>&gt;64 (R) 2 (R)</td>
<td>SC14121</td>
<td>ST1901</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest‡</td>
<td>&gt;256 (R) 0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Beta-lactamase
†Interpretative criteria for ciprofloxacin (Susceptible ≤0.06 µg/mL, Resistant ≥1.0 µg/mL), penicillin (Susceptible ≤0.06 µg/mL, Resistant ≥2.0 µg/mL) and tetracycline (Susceptible ≤0.25 µg/mL, Resistant ≥2.0 µg/mL), cefixime (Susceptible ≤0.25 µg/mL) and ceftriaxone (Susceptible ≤0.25 µg/mL) were in accordance with the Clinical Laboratory Standards Institute. The Gonococcal Isolate Surveillance Project’s alert values were used to interpret the MIC values for azithromycin (Susceptible ≤0.1 µg/mL, Resistant ≥0.25 µg/mL). The GISP alert criteria (Decreased susceptible ≥0.05 µg/mL was also used for cefixime and ceftriaxone since CLSI does not report a resistant MIC value. There are no interpretative criteria for gentamicin. R refers to resistant, DS is decreased susceptible, S is susceptible and ND is not determined.
‡Etest MIC values are rounded up to the nearest doubling dilution for comparison to agar dilution results as recommended by the manufacturer.